In short
Clinical trials are investigating Ro7269162 in people at risk for or already in the prodromal stage of Alzheimer’s disease. These studies look at safety, tolerability, and long-term biomarker changes, including brain amyloid measured by PET scans. The goal is to understand whether Ro7269162 can affect disease-related changes in this target population.
Key points
- Clinical trials of Ro7269162 are studying people at risk for Alzheimer’s disease and people in the prodromal stage of the disease. The main trial is a Phase 2 interventional study with 247 participants. Researchers are looking at safety, tolerability, and long-term biomarker effects, especially brain amyloid changes measured by PET scans. The study also tracks adverse events, vital signs, ECG results, suicide risk screening, and lab findings. The trial is authorised and uses oral Ro7269162 along with imaging agents for amyloid scans. The focus is on early disease changes rather than late-stage Alzheimer’s disease.
Trial overview
The main study of Ro7269162 is an interventional Phase 2 trial in Alzheimer’s disease. It is designed to evaluate safety and long-term biomarker effects in people at risk for or already in the prodromal stage of Alzheimer’s disease.
The trial is authorised and plans to include 247 participants. The study title shows that the researchers are especially interested in safety and changes in brain amyloid over time.
Who can participate
This study targets people who are at risk for Alzheimer’s disease or who are in the prodromal stage of the disease. The prodromal stage means very early disease changes, when symptoms may be mild or just starting.
The trial data do not list detailed inclusion or exclusion rules, so the available information only shows the general target population.
What is being measured
The primary outcomes include the nature, incidence, severity, and outcome of adverse events, which are unwanted medical problems that happen during a study. The study also tracks changes from baseline in vital signs, ECG results, Columbia-Suicide Severity Rating Scale findings, and safety laboratory tests.
Another main outcome is change from baseline in brain amyloid load, measured by an amyloid PET scan. Amyloid is a protein that can build up in the brain in Alzheimer’s disease, and PET scans are imaging tests that help researchers measure it.
Trial phase and status
The study is in Phase 2, which usually means researchers are looking more closely at safety and early signs of effect in a specific group of patients. The trial status is listed as authorised.
Because this is a Phase 2 study, the main focus is not final proof of benefit, but whether the study treatment can be studied safely and whether it changes disease-related markers.
Study treatments and scans
The trial includes daily oral dosing of Ro7269162 and compares it with placebo Ro7269162 in parts of the study design. The source also lists two imaging agents used for amyloid scans: FLUTEMETAMOL (18F) and FLORBETABEN (18F).
These scan agents are used with PET imaging to help measure amyloid in the brain. The study brief summary says the goal is to investigate the safety and tolerability of daily oral dosing of Ro7269162 and its effect on brain amyloid accumulation.
Why this study matters
Alzheimer’s disease is a serious brain condition, and studies in early stages may help researchers learn whether treatment can change disease-related markers before symptoms become more advanced. This trial is focused on early disease risk and prodromal disease, so it may help build evidence for future research in earlier Alzheimer’s care.